Allergan (AGN) is scheduled to report Q4 earnings before the market open on Tuesday February 5, with a conference call scheduled for 11:00 am ET. Allergan is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter consumer products... EXPECTATIONS: Analysts are looking for EPS of $1.18 on revenue of $1.51B, according to First Call. The consensus range for EPS is $1.13-$1.21 on revenue of $1.48- $1.53B... LAST QUARTER: Allergan reported Q3 EPS of $1.06 against estimates of $1.04 on revenue of $1.41B against estimates of $1.43B. At the time of its Q3 earnings release, Allergan gave Q4 EPS guidance of $1.18-$1.20 against consensus estimates of $1.20 on revenue of $1.47B-$1.55B on consensus estimates of $1.51B... STREET RESEARCH: In a research note from February 4, Buckingham said it is keeping its Buy rating on Allergan shares on attractive longer term growth prospects, but noted that with shares up ~ 17% year-to-date, some volatility in share price should be expected. The firm also noted that it would be more aggressive on shares with any potential weakness. On January 25, Leerink raised Allergan's price target to $116-$117 from $103-$104 to reflect its positive view of recent acquisitions and long-term prospects for the company. Leerink kept an Outperform rating on the stock... PRICE ACTION: Allergan shares are up approximately 15% since January 1. In late afternoon trading, Allergan shares are down about 1.5% to $105.30.